• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • MSD’s Keytruda takes lead in squamous NSCLC trials pharmatimes
    June 06, 2018
    MSD’s Keytruda has shown a greater benefit than Roche’s Tecentriq in separate (and incomparable) clinical trials exploring the effectiveness of the anti-PD-1 therapies in treatment-naiive patients with squamous non-small cell lung cancer.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service